^
Association details:
Biomarker:KRAS G12C
Cancer:Non Small Cell Lung Cancer
Drug:GEC-255 (KRAS G12C inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Excerpt:
...Has histologically or cytologically confirmed advance tumors with KRAS p.G12C mutation and has poor response to standard of care therapy or intolerant to standard of care therapies (chemotherapy, targeting therapy or immunotherapy)....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.

Published date:
05/25/2023
Excerpt:
GEC255 has been well tolerated at the doses tested and has shown encouraging anticancer activity to advanced NSCLC patients with KRASG12C mutation pts.
DOI:
10.1200/JCO.2023.41.16_suppl.9112